After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline ...
Atara Biotherapeutics (ATRA) announced that the FDA has placed a clinical hold on Atara’s active investigational new drug, or IND, ...
Atara Biotherapeutics (ATRA) plans to cut around 50% of its workforce, just a little over a week after the FDA declined to ...
Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is ...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...
Atara Biotherapeutics experiences a plunge in share prices after the Food and Drug Administration holds up approval of a drug ...
NEW YORK CITY, NY / ACCESS Newswire / January 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
H.C. Wainwright maintained its Neutral stance on Atara Biotherapeutics stock (NASDAQ:ATRA), following the company's announcement of a significant workforce reduction. According to InvestingPro data, ...
On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.’s (NASDAQ:ATRA) ...
--(BUSINESS WIRE)--Atara Biotherapeutics ... These INDs include the EBVALLO TM (tabelecleucel) program as monotherapy treatment for adult and pediatric patients two years of age and older with ...
--(BUSINESS WIRE)-- Atara Biotherapeutics ... The clinical hold for EBVALLO is directly linked to inadequately addressed GMP compliance issues identified during the pre-license inspection of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback